Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Intensive chemotherapy may benefit elderly patients with acute myeloid leukemia

The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months, according to a study published online today in Blood, the journal of the American Society of Hematology. AML is the most common form of acute leukemia among adults and is a rapidly growing cancer of the bone marrow that requires immediate treatment. The average age at diagnosis is 67, and more than 12,000 people will be diagnosed with AML this year (according to the National Cancer Institute).

29 Jul 2010

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2010. For the second quarter, AMAG reported total revenue of $18.8 million, including $16.0 million of Feraheme® (ferumoxytol) Injection for intravenous (IV) use net product revenues.

29 Jul 2010

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

Pain Therapeutics, Inc., a biopharmaceutical company, today reported second quarter financial results. Net loss for the quarter ended June 30, 2010 was $0.8 million, or $0.02 per share, compared to net loss of $34,000, or $0.00 per share, for the second quarter of 2009. Pain Therapeutics had cash, cash equivalents and marketable securities of $176.2 million, or about $4.14 cash per share, and no debt as of June 30, 2010.

28 Jul 2010

HemaQuest closes additional $4M to Series B financing

HemaQuest Pharmaceuticals, a clinical stage biotechnology company developing small molecule therapeutics for sickle cell disease, beta thalassemia and EBV-related cancers, announced today the closing of an additional $4M to its Series B financing by new investor, Latterell Venture Partners. This investment brings the total Series B financing to $16M.

28 Jul 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Allos Therapeutics, Inc. today reported its financial results and business highlights for the quarter and six months ended June 30, 2010.

28 Jul 2010

Vitro Diagnostics, Mokshagundam Biotechnologies enter contract to develop stem cell-derived food

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that it has entered into a contract with Mokshagundam Biotechnologies, a private research organization established to develop alternative meat sources, to develop cell culture medium for use in exploration of alternative food sources derived from stem cells.

28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Sysmex America to debut expanded cell image analysis portfolio at AACC Annual Conference

Sysmex America, Inc., a leading medical diagnostic instrument manufacturer and information systems developer, today announced plans to debut its expanded cell image analysis portfolio during this year's American Association of Clinical Chemistry's (AACC) Annual Conference and Clinical Lab Expo July 25 - 29 in Anaheim, California.

From Sysmex America, Inc. 27 Jul 2010

Navigating Cancer creates new application to help patients manage, update medical history

Navigating Cancer is putting the power of cancer treatment advocacy and management into the hands of cancer patients. The free website, which empowers cancer patients to take an active role in their care and partner more closely with their physicians during treatment, has created a unique medical history form that enables patients to manage and update their medical history on demand.

27 Jul 2010

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

26 Jul 2010

prIME Oncology awarded Provisional Accreditation to provide medical education for physicians

prIME Oncology has been awarded Provisional Accreditation to provide continuing medical education for physicians by the Accreditation Council for Continuing Medical Education in the US. Provisional Accreditation is the standard status for initial, or first-time, applicants.

26 Jul 2010

GRB7 gene drives an aggressive form of breast cancer, researchers find

Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient's treatment and enable physicians to provide a more accurate prognosis.

23 Jul 2010

Vermillion to complete relocation of corporate offices to Austin, Texas by September 2010

Vermillion, Inc., a molecular diagnostics company, today announced that it is relocating its corporate headquarters from Fremont, California to Austin, Texas. Vermillion has executed a two-year lease for a new principal place of business at 12117 Bee Cave Road, Building Two, Suite 100, Austin, TX 78731. Vermillion will continue to operate research and development, regulatory and quality operations in California. All other functions will be conducted at the Austin offices.

23 Jul 2010

IDEXX Laboratories second-quarter 2010 revenues increase 6% to $281.5 million

IDEXX Laboratories, Inc., today reported that revenues for the second quarter of 2010 increased 6% to $281.5 million, from $265.7 million for the second quarter of 2009. Organic revenue growth, as defined below, was 5%. Earnings per diluted share for the quarter ended June 30, 2010 increased 13% to $0.62, compared to $0.55 for the same period in the prior year.

23 Jul 2010

ASH to honor six scientists for treatment of hematologic diseases

The American Society of Hematology (ASH), the world's largest professional society of blood specialists, will honor six scientists who have made significant contributions to the understanding and treatment of hematologic diseases. These awards will be presented at the 52nd ASH Annual Meeting taking place December 4-7 in Orlando.

23 Jul 2010

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that a 44-year-old female patient with advanced acute promyelocytic leukemia (APL) achieved molecular complete remission with no evidence of disease in the blood cells and/or bone marrow following treatment with CytRx's oncology drug candidate tamibarotene.

23 Jul 2010

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2010.

22 Jul 2010

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

21 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Abbott today announced financial results for the second quarter ended June 30, 2010.

21 Jul 2010

Hematology News and Research

Further Reading

Intensive chemotherapy may benefit elderly patients with acute myeloid leukemia

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

HemaQuest closes additional $4M to Series B financing

Allos reports net loss of $20.0 million for second-quarter 2010

Vitro Diagnostics, Mokshagundam Biotechnologies enter contract to develop stem cell-derived food

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Sysmex America to debut expanded cell image analysis portfolio at AACC Annual Conference

Navigating Cancer creates new application to help patients manage, update medical history

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

prIME Oncology awarded Provisional Accreditation to provide medical education for physicians

GRB7 gene drives an aggressive form of breast cancer, researchers find

Vermillion to complete relocation of corporate offices to Austin, Texas by September 2010

IDEXX Laboratories second-quarter 2010 revenues increase 6% to $281.5 million

ASH to honor six scientists for treatment of hematologic diseases

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Genzyme second-quarter revenue decreases to $1.08 billion

Researchers find that increase in leptin may promote colorectal neoplasms

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News